Mesothelioma

The Halpern Law Firm Continues to Grow, Welcoming Five New Team Members

Retrieved on: 
Friday, May 26, 2023
Kutztown University of Pennsylvania, Temple University Beasley School of Law, District attorney, Communication, Food, University, Private law, University of Central Missouri, Drexel University, Communication studies, Government, Asbestos, Mesothelioma, Associate attorney, Growth, Digital, Wilfrid Sellars, University of Pittsburgh School of Law, Pharmaceutical industry, Nursing, Construction, Law, Animation

PHILADELPHIA, May 26, 2023 /PRNewswire-PRWeb/ -- The Halpern Law Firm, a preeminent Pennsylvania-based law firm specializing in asbestos and mesothelioma cases, continues to thrive and is delighted to announce the addition of five new members to their dynamic team: Chelsea Williams, Mark Watkins, Daniel Liberio, Thaddeus Kotarski, and Jeff Nelson. This expansion further reinforces the firm's unwavering commitment to providing exceptional legal services to victims of mesothelioma and other asbestos related diseases.

Key Points: 
  • PHILADELPHIA, May 26, 2023 /PRNewswire-PRWeb/ -- The Halpern Law Firm , a preeminent Pennsylvania-based law firm specializing in asbestos and mesothelioma cases, continues to thrive and is delighted to announce the addition of five new members to their dynamic team: Chelsea Williams, Mark Watkins, Daniel Liberio, Thaddeus Kotarski, and Jeff Nelson.
  • Daniel Liberio is a 2023 graduate of Temple University Beasley School of Law and has joined our firm as a Law Clerk.
  • Thaddeus Kotarski, a recent graduate of the University of Pittsburgh School of Law, brings a diverse and impressive legal background to the team.
  • "The diverse skills and experiences of our new team members will undoubtedly contribute to our ongoing mission of representing and fighting for the rights of asbestos victims," says Dave Halpern , Founding Attorney of The Halpern Law Firm.

Owkin Receives European Medicines Agency Letter of Support for Innovative AI-Driven Approach to Oncology Trial Analysis

Retrieved on: 
Tuesday, May 16, 2023
Hepatocellular carcinoma, Mesonet, Deep learning, European Medicines Agency, Survival, Clinical trial, Prognosis, Biomarker, Optimization, EMA, Patient, Mesothelioma, Drug discovery, AI, FDA, Letter, HCC, Dependent and independent variables, Biopsy, Medical device, Pharmaceutical industry

Two Owkin AI models significantly improve the discrimination accuracy for overall survival in hepatocellular carcinoma and mesothelioma.

Key Points: 
  • Two Owkin AI models significantly improve the discrimination accuracy for overall survival in hepatocellular carcinoma and mesothelioma.
  • Therefore, Owkin is encouraged to use their approach in future trials and do additional prospective validation.
  • Felix Balazard, Director of Optimized Development at Owkin said: "This EMA letter of support offers a clear regulatory path for integrating AI models based on histopathology into the analysis of randomized clinical trials.
  • With Owkin's Federated Research Network, it can develop on-demand prognostic scores for other indications, which can further reduce clinical trial failure rates.

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

Retrieved on: 
Friday, May 12, 2023
TNBC, Triple-negative breast cancer, Euronext Growth, TAA, Neoplasm, Gene editing, UCAR, Cancer, Cancer-associated fibroblast, Breast, FAP, Heterotrimeric G protein, CAF, Malignancy, Mesothelin, CAR, Patient, Extracellular matrix, TME, ISCB Senior Scientist Award, Mesothelioma, Cytokine, Tumor microenvironment, Vaccine, Medical imaging, Cellectis

Adoptive cell therapy based on chimeric antigen receptor-engineered T (CAR-T) cells has proven to be lifesaving for many cancer patients.

Key Points: 
  • Adoptive cell therapy based on chimeric antigen receptor-engineered T (CAR-T) cells has proven to be lifesaving for many cancer patients.
  • However, its therapeutic efficacy has so far been restricted to only a few malignancies, with solid tumors proving to be especially recalcitrant to efficient therapy.
  • Poor intra-tumor infiltration by T cells and T cell dysfunction due to a desmoplastic, immunosuppressive microenvironment are key barriers for CAR T-cell success against solid tumors.
  • CAF depletion in stroma rich solid tumors can thus provide an opportunity to convert immune evasive tumors susceptible to tumor-antigen CAR T-cell cytotoxicity.

Plaintiffs' Steering Committee in the Federal Talc Multidistrict Litigation: Leadership in Talc MDL Litigation Applauds Sen. Durbin for Remarks in CNN Report

Retrieved on: 
Tuesday, May 9, 2023
Other Consumer, Women, Cosmetics, Other Health, Retail, Parenting, Men, Legal, Baby, Maternity, Oncology, Family, Consumer, Professional Services, Public Policy, Government, General Health, Courts, Health, Other Retail, Supermarket, Talc, Senate Judiciary Committee reviews of nominations to the Supreme Court of the United States, Interview, Senate, Perception, Woman, Ashcraft, Lawyer, United States Court of Appeals for the Third Circuit, CNN, J&J, Asbestos, Mesothelioma, Court, Johnson & Johnson, FDA, Ovarian cancer, Shaken, Bankruptcy, Pharmaceutical industry

That move effectively created further delays and again denied the rights of talc victims to pursue their claims through multidistrict litigation, as well as state courts.

Key Points: 
  • That move effectively created further delays and again denied the rights of talc victims to pursue their claims through multidistrict litigation, as well as state courts.
  • In the second bankruptcy filing, J&J’s proposed “funding agreement” for expenses related to the litigation was drastically reduced to create a perception of financial distress lacking in the first filing.
  • The CNN documentary illuminated evidence that for many years Johnson & Johnson knew about the existence of asbestos in its talc but sought to conceal it.
  • The company has announced a global ban on sales of baby powder containing talc by the end of this year.

Russell Budd Recognized as 2023 Trailblazers Plaintiffs’ Lawyer by the National Law Journal

Retrieved on: 
Tuesday, May 2, 2023
Public Policy, Government, Legal, Professional Services, State, Local, Mesothelioma, The National Law Journal, Trailblazer, Policy, MDL, Baron, Asbestos, Baron & Budd, P.C., Pharmacy, Pharmaceutical industry

The national law firm of Baron & Budd is pleased to announce that President and Managing Shareholder Russell W. Budd has been recognized as a 2023 Trailblazers Plaintiffs’ Lawyer by The National Law Journal.

Key Points: 
  • The national law firm of Baron & Budd is pleased to announce that President and Managing Shareholder Russell W. Budd has been recognized as a 2023 Trailblazers Plaintiffs’ Lawyer by The National Law Journal.
  • Serving as a Baron & Budd shareholder since 1985 and president and managing shareholder since 2002, Budd presides over one of the nation’s largest plaintiffs’ firms.
  • Under Budd’s leadership, Baron & Budd has garnered significant national recognition for cutting-edge litigation and settlements.
  • Most recently, Budd was appointed to the Plaintiffs’ Settlement Negotiation Team for In re National Prescription Opiate Litigation, MDL 2804.

Avenge Bio Announces Successful Completion of First Dose Level Cohort in Phase 1/2 Clinical Trial of AVB-001 for the Treatment of Ovarian Cancer

Retrieved on: 
Wednesday, April 26, 2023
Adenocarcinoma, Mesothelioma, Toxicity, Pharmacokinetics, Ovarian cancer, Patient, MD, Ovary, IP, Safety, Pharmaceutical industry, Vaccine

and QUINCY, Mass., April 26, 2023 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge"), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the successful completion of the first dose cohort in a Phase 1/2 clinical trial of AVB-001 in patients with refractory ovarian cancer.

Key Points: 
  • and QUINCY, Mass., April 26, 2023 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge"), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the successful completion of the first dose cohort in a Phase 1/2 clinical trial of AVB-001 in patients with refractory ovarian cancer.
  • The dose escalation trial evaluates the safety and tolerability, as well as preliminary efficacy, of AVB-001 administered intraperitoneally across a series of ascending dose-level cohorts.
  • "We are pleased to complete the first dose cohort in this Phase 1/2 clinical trial.
  • Although early, we are encouraged by the initial observations in this first dose level indicating the potential for this allogeneic cell-based immunotherapy.

Levy Konigsberg Files Motion to Consolidate 22 Talc Mesothelioma Lawsuits for Trial Against Johnson & Johnson

Retrieved on: 
Tuesday, April 25, 2023
Talc, LTL, Senate, Königsberg, Superior court, Woman, United States Court of Appeals for the Third Circuit, J&J, Texas two-step bankruptcy, Motion, United States bankruptcy court, Sacramento County Superior Court, Johnson & Johnson, Asbestos, Mesothelioma, Johnson's Baby, Safety, United States Senate, Bankruptcy, Pharmaceutical industry, Birth control, Cryptocurrency

NEW YORK, April 24, 2023 /PRNewswire/ -- Levy Konigsberg, a leading national law firm representing victims of corporate misconduct, has filed a motion to consolidate for trial the cases of 22 people diagnosed with mesothelioma caused by asbestos in Johnson's Baby Powder. The motion was filed in the Superior Court in Middlesex County, New Jersey, and seeks to have a jury evaluate the evidence of Johnson & Johnson's (J&J) egregious corporate wrongdoing.

Key Points: 
  • Levy Konigsberg files motion in New Jersey state court to consolidate for trial 22 mesothelioma cases caused by asbestos in Johnson's Baby Powder.
  • NEW YORK, April 24, 2023 /PRNewswire/ -- Levy Konigsberg, a leading national law firm representing victims of corporate misconduct, has filed a motion to consolidate for trial the cases of 22 people diagnosed with mesothelioma caused by asbestos in Johnson's Baby Powder.
  • The ruling allows these 22 mesothelioma cases, and other filed against J&J, to proceed toward long-awaited jury trials.
  • Levy Konigsberg LLP has been representing victims of mesothelioma in civil lawsuits since 1985.

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Immortalised cell line, MTAP, KRAS, AACR, Therapy, GBM, MTA, BRCA1, Therapeutic index, Clinical trial, American Association for Cancer Research, Ovary, Breast, Prostate, Publication, Lung cancer, Carcinoma, Glioblastoma, USP1, PRMT5, Non-small-cell lung cancer, Tango, Development, RCOR1, Patient, EGFR, Cancer, Annual general meeting, Mesothelioma, Escape Room, Poster, BRCA2, PD-1, Horizon, IND, PARP, Cholangiocarcinoma, Pharmaceutical industry, Vaccine, Medical imaging, Birth control, Fertilizer, STK11, Research

BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

Key Points: 
  • BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.
  • “At this year’s AACR Annual Meeting, we presented preclinical data from four programs across our precision oncology portfolio, including two oral presentations.
  • It’s a tremendously exciting time for the field of precision oncology as we and others move into evaluating novel and previously not addressable targets.
  • TNG908 is 15X selective for MTAP-null cancer cells with the potential for broad clinical activity and a large therapeutic index.

ONCOTELIC PROVIDES YE 2022 FINANCIAL RESULTS COMPARED TO YE 2021 PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE

Retrieved on: 
Monday, April 17, 2023
Pancreatic cancer, DAO, Blockchain, US Foods, Biomedical Advanced Research and Development Authority, TGF, Glioma, EZ, COVID-19, Clinical trial, Decentralized autonomous organization, FYE, G&A, IIS, Veteran, Lung cancer, Sale, Trial of the century, JV, Development, US, Melanoma, Randomness, Mesothelioma, CFO, Architecture, Fred Hutchinson Cancer Research Center, BARDA, US FDA, Food, Security (finance), Pharmaceutical industry, Cryptocurrency, Token, Patient, AI

In 2022 and continuing in the first quarter of 2023, the Company has made significant progress in various areas.

Key Points: 
  • In 2022 and continuing in the first quarter of 2023, the Company has made significant progress in various areas.
  • The Company also attended and participated in over ten different conferences and events during 2022 and made presentations at several.
  • The Company was also awarded funding from the Biomedical Advanced Research and Development Authority (“BARDA”) for the development of OT-101 for long COVID-19.
  • Highlights post close of FYE 2022:
    “FY 2022 was a challenging yet exciting year for all of us at Oncotelic,” said Amit Shah, CFO of Oncotelic.

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Retrieved on: 
Monday, April 17, 2023
KRAS, AACR, Doctor of Philosophy, Nephrotoxicity, Chromatin, EHE, Therapeutic index, Cancer, American Association for Cancer Research, Toxicity, VGLL4, MEK, TEAD, TEAD1, Beauty, RAS, Patient, EGFR, Mesothelioma, Biology, Hippopotamus, Pharmaceutical industry, Vaccine

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will present preclinical data in two poster presentations highlighting the Company’s novel Hippo pathway inhibitor, IK-930, at the American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, FL from April 14-19, 2023.

Key Points: 
  • Data being shared today reveals that IK-930 selectively binds and inhibits TEAD1 and further describes the mechanism for its antitumor activity.
  • Key advantages demonstrated in the nonclinical studies include IK-930’s superior tolerability and comparable antitumor activity compared to panTEAD inhibition, resulting in a significantly improved projected therapeutic window in cancer patients.
  • IK-930 was designed as a TEAD1-selective inhibitor to avoid on-target renal toxicity expected from panTEAD inhibition.
  • TEAD1 is the most highly expressed TEAD paralog in mesothelioma and epithelioid hemangioendothelioma (EHE).